DataTeams, a company specializing in clinical data management, announced on the 11th that it has obtained the 'Certified Clinical Data Manager (CCDM) Industry Partner' certification from the non-profit international organization, the Society for Clinical Data Management (SCDM). <br>[Photo by DataTeams]

DataTeams, a company specializing in clinical data management, announced on the 11th that it has obtained the 'Certified Clinical Data Manager (CCDM) Industry Partner' certification from the non-profit international organization, the Society for Clinical Data Management (SCDM).
[Photo by DataTeams]

View original image

[Asia Economy Reporter Chunhee Lee] DataTeams, a company specializing in clinical data management, announced on the 11th that it has obtained the 'Certified Clinical Data Manager (CCDM) Industry Partner' certification from the non-profit international organization, the Society for Clinical Data Management (SCDM).


To acquire the CCDM Industry Partner qualification, at least 25% or 10 or more of the clinical data managers in the company must hold the CCDM certification. Currently, only 17 companies worldwide, including DataTeams, have obtained this partner certification. DataTeams currently has over 60% of its data managers holding the CCDM certification.


DataTeams, established in 2021, is a company specializing in clinical data management services. It is composed of clinical data management experts who handle all aspects of data, from electronic data capture (EDC) design for clinical trials to submitting clinical data in the Clinical Data Interchange Standards Consortium (CDISC) format to overseas regulatory agencies such as the U.S. Food and Drug Administration (FDA).


With this certification, DataTeams has demonstrated international-level capabilities and expertise in clinical data management tasks.



Seokmin Yoon, CEO of DataTeams, stated, “This is the result of continuous efforts to provide data management services that meet international standards,” adding, “Through this international certification, we have gained the conditions to become partners not only with domestic but also with overseas pharmaceutical companies in the U.S., Japan, and other countries, which is significant.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing